文献速递肿瘤 PET/CT核素与放射性配体治疗

89Zr-DFO-MSTP2109A抗STEAP1抗体PET/CT显像在转移性去势抵抗性前列腺癌中的应用

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.
PubMed 文献 · J Nucl Med · 2019-05-03

结果显示该抗体耐受良好,骨和软组织病灶摄取高(骨中位SUVmax 20.6,软组织16.8),组织学阳性病灶的真阳性率估计为86%(95%CI 75%-100%),但SUVmax与STEAP1免疫组化、ADC治疗结局等无相关性。

要点

  • 89Zr-DFO-MSTP2109A在mCRPC骨和软组织病灶中显示高摄取,耐受良好。
  • 组织学阳性病灶的PET真阳性率估计为86%(95%CI 75%-100%)。
  • 肿瘤SUVmax与STEAP1免疫组化及ADC治疗结局无相关性。

核心结论

  • 89Zr-DFO-MSTP2109A耐受良好,在mCRPC骨和软组织病灶中显示定位,值得作为STEAP1靶向治疗的伴随诊断进一步探索。

主要发现

  • 未发生显著毒性。
  • 骨病灶中位SUVmax为20.6,软组织病灶中位SUVmax为16.8。
  • 活检的17个病灶中16个在89Zr-DFO-MSTP2109A上为阳性,所有部位组织学均为阳性(1例重复活检)。
  • 贝叶斯分析估计组织学阳性病灶中86%为影像学真阳性(95%CI 75%-100%)。
  • 肿瘤SUVmax与STEAP1免疫组化、ADC治疗后生存、ADC治疗周期数或前列腺特异性抗原水平变化均无相关性。

临床怎么用

  • 该显像剂可用于检测mCRPC骨和软组织病灶,并可能作为STEAP1靶向治疗的伴随诊断工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified target in prostate cancer. We evaluated the ability of PET/CT with 89Zr-DFO-MSTP2109A, an antibody that recognizes STEAP1, to detect lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Nineteen mCRPC patients were prospectively imaged using approximately 185 MBq/10 mg of 89Zr-DFO-MSTP2109A. 89Zr-DFO-MSTP2109A PET/CT images obtained 4-7 d after injection were compared with bone and CT scans. Uptake in lesions was measured. Fifteen patients were treated with an antibody-drug conjugate (ADC) based on MSTP2109A; ADC treatment-related data were correlated with tumor uptake by PET imaging. Bone or soft-tissue biopsy samples were evaluated. Results: No significant toxicity occurred. Excellent uptake was observed in bone and soft-tissue disease. Median SUVmax was 20.6 in bone and 16.8 in soft tissue. Sixteen of 17 lesions biopsied were positive on 89Zr-DFO-MSTP2109A, and all sites were histologically positive (1 on repeat biopsy). Bayesian analysis resulted in a best estimate of 86% of histologically positive lesions being true-positive on imaging (95% confidence interval, 75%-100%). There was no correlation between SUVmax tumor uptake and STEAP1 immunohistochemistry, survival after ADC treatment, number of ADC treatment cycles, or change in prostate-specific antigen level. Conclusion:89Zr-DFO-MSTP2109A is well tolerated and shows localization in mCRPC sites in bone and soft tissue. Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Carrasquillo JA, Fine BM, Pandit-Taskar N, et al. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. J Nucl Med. 2019. PMID: 31053681. doi:10.2967/jnumed.118.222844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。